The following stories appear in full on Today's Vidyya Medical News Service Web site.
A consultation of international experts, convened by the World Health Organization (WHO) on 12-13 March 2001, reviewed the existing state of evidence on air travel and venous thrombosis and concluded that further research is needed into the matter.
For more information: Scientific Experts And Airline Industry Call For Further Study Of Venous Thrombosis
The results of a follow-up analysis of the landmark Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study provide important new evidence regarding the benefits of cholesterol-lowering treatment with pravastatin for women with a prior history of coronary heart disease.
For more information: Additional Information About Long-Term Benefits Of Pravastatin Therapy Gleaned From Follow Up Of A Landmark Lipid Trial
Study results presented yesterday at the American College of Cardiology's (ACC) annual meeting showed that elderly hypertensive osteoarthritis (OA) patients taking Vioxx® (rofecoxib) experienced a statistically significant increase (approximately 3 mm Hg) in mean systolic blood pressure compared with those taking Celebrex® (celecoxib capsules). In comparison, Celebrex patients showed no increase in mean systolic blood pressure.
For more information: Study Demonstrates Differences In Blood Pressure And Edema Between Celebrex® And Vioxx®
An analysis of more than 6,000 patients treated for acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction), indicates that those who received the blood thinner Lovenox (enoxaparin sodium) Injection prior to undergoing percutaneous coronary intervention (PCI) fared better than patients given unfractionated heparin. The analysis, based on the landmark ESSENCE and TIMI 11B* trials, was presented yesterday at the 50th Annual Scientific Session of the American College of Cardiology.
For more information: Prior To Coronary Interventions, Injection With Lovenox ® May Be Of Potential Benefit
Pfizer Inc. said today that men with erectile dysfunction (ED) who have been prescribed Viagra (sildenafil citrate) do not have an increased risk of heart attack or death from ischemic heart disease, according to results from the first phase of a large-scale, observational study of Viagra presented at the annual meeting of the American College of Cardiology (ACC).
For more information: Viagra Safe For Men With Healthy Hearts
Today's Vidyya articles are:
As always, we hope you enjoy the issue.